The Big Pore Theory could cure chronic pain

April 14, 2017 by Elodie Gazave

Cornell University researchers have produced for the first time an image of P2X7, a receptor associated with chronic pain. Visualizing the shape of the receptor has also allowed them to make a second groundbreaking discovery: They observed that five painkiller molecules they tested did not bind the receptor at the place they expected, which could explain why these painkillers lack efficacy in human patients.

This discovery, published Dec. 9, 2016, in the journal eLife, lays the foundations to create targeted and effective to manage .

Chronic pain affects 10 percent of the adult population. It also accompanies conditions such as rheumatoid arthritis and migraine, for which pain management remains crucial in patient care. However, chronic pain does not always respond to existing analgesic drugs.

The lack of effective medicines is partly due to the limited knowledge scientists have about pain. Cornell researchers have been looking into a receptor called P2X7, which binds a molecule called ATP.

Many drugs targeting P2X7 work by competing for space with the ATP molecule, occupying the groove at the surface of P2X7 where ATP would naturally bind. Scientist believe that preventing ATP from binding to the P2X7 receptor should block the pain signal.

Research in animal models had shown promising results for drugs targeting P2X7. However, clinical trials in humans were much less satisfactory.

To understand why these trials failed in humans, a team led by Toshimitsu Kawate, assistant professor in the College of Veterinary Medicine's Department of Molecular Medicine, decided to visualize the shape of the receptor. The results were astonishing, he said: "The drugs were not where we expected them to bind. We were actually shocked."

To make this discovery, Kawate and his team had to see the structure of the receptor. Using X-ray crystallography at the Cornell High Energy Synchrotron Source (CHESS), Kawate created an image of the receptor at a resolution of 3.5 angstroms – about a thousandth of the width of hair.

They found that P2X7 is an "elegant" molecule comprising three dolphin-shaped subunits. The "dolphin's fluke" of the three subunits is anchored in the . These flukes work as a "camera shutter" that can twist open or close – a motion triggered by ATP.

In absence of ATP, the flukes form a closed conformation. When ATP molecules bind to the dolphin's upper body, the flukes rotate in a spiraling motion and form a in the cell membrane, allowing water, ions and other small molecules to pass through.

P2X7 has one interesting particularity compared with other ion-channel proteins. It mainly functions as a normal pore, but sometimes it converts into a big pore and allows molecules up to 900 dalton, a unit that quantifies mass at atomic levels, through the membrane.

This big pore conversion process is what Kawate wants to study next to learn why and how frequently big pore conversion happens. Some theorize that under pathological conditions, big pore conformation might be what creates pain. For example, pain-causing molecules could be released from inside the cell to the surrounding tissues through the P2X7 channel. Kawate is trying to design genetic or chemical traps to capture P2X7 big pores so that he can visualize the structure and understand their biological significance.

Understanding under which physiological conditions and how the conversion happens may help manipulate the receptor, for example to design that can trap P2X7 and prevent its conversion to a big pore state. "This could be useful to treat several types of chronic , for example associated with irritable bowel syndrome, that are proposed to be caused by the big pore of P2X7."

Explore further: Study suggests new way to treat chronic pain

More information: Akira Karasawa et al. Structural basis for subtype-specific inhibition of the P2X7 receptor, eLife (2016). DOI: 10.7554/eLife.22153

Related Stories

Study suggests new way to treat chronic pain

March 26, 2012
Nearly one in five people suffers from the insidious and often devastating problem of chronic pain.

Research sheds new light on how blood clots form

June 13, 2011
Scripps Research Institute scientists have discovered new elements of the blood clot-formation process. The findings could lead to better drugs for preventing heart attacks and other clot-related conditions.

Scientists reveal non-addictive pathway to pain relief

January 12, 2017
OHSU research suggests an avenue for developing treatments for chronic pain that harness the medicinal properties of cannabis while minimizing the threat of addiction.

Researchers develop computer simulation of body's heat response

September 20, 2016
For the first time, scientists at the M.M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences have successfully used computer-generated simulations to study the TRPV1-receptor ...

Naturally occurring protein has a role in chronic pain

June 12, 2012
Researchers in France and Sweden have discovered how one of the body's own proteins is involved in generating chronic pain in rats. The results, which also suggest therapeutic interventions to alleviate long-lasting pain, ...

Recommended for you

Inflammation trains the skin to heal faster

October 18, 2017
Scars may fade, but the skin remembers. New research from The Rockefeller University reveals that wounds or other harmful, inflammation-provoking experiences impart long-lasting memories to stem cells residing in the skin, ...

Large variety of microbial communities found to live along female reproductive tract

October 18, 2017
(Medical Xpress)—A large team of researchers from China (and one each from Norway and Denmark) has found that the female reproductive tract is host to a far richer microbial community than has been thought. In their paper ...

Study of what makes cells resistant to radiation could improve cancer treatments

October 18, 2017
A Johns Hopkins University biologist is part of a research team that has demonstrated a way to size up a cell's resistance to radiation, a step that could eventually help improve cancer treatments.

New approach helps rodents with spinal cord injury breathe on their own

October 17, 2017
One of the most severe consequences of spinal cord injury in the neck is losing the ability to control the diaphragm and breathe on one's own. Now, investigators show for the first time in laboratory models that two different ...

Pair of discoveries illuminate new paths to flu and anthrax treatments

October 17, 2017
Two recent studies led by biologists at the University of California San Diego have set the research groundwork for new avenues to treat influenza and anthrax poisoning.

New method to measure how drugs interact

October 17, 2017
Cancer, HIV and tuberculosis are among the many serious diseases that are frequently treated with combinations of three or more drugs, over months or even years. Developing the most effective therapies for such diseases requires ...


Adjust slider to filter visible comments by rank

Display comments: newest first

1 / 5 (1) Apr 16, 2017
Cornell might consult their butterfly pheromone chemists on this. This looks like a pheromone receptor protein. Synergistic species specific reception of multicomponent mixtures of pheromone stereochemistry would diminish chronic pain. Try 250mg of healthy adult male facial skin surface lipid pheromone (usually passed in innocent kissing). It has 735 components and their delivery in social behavior would reward socially appropriate behavior. Heroes should get lots of kisses anyway! They need them.
5 / 5 (1) Apr 16, 2017
"Synergistic species specific reception of multicomponent mixtures of pheromone stereochemistry would diminish chronic pain. Try 250mg of healthy adult male facial skin surface lipid pheromone (usually passed in innocent kissing). It has 735 components . "
- cite your source(s) please.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.